Ranbaxy recalls generic Lipitor in United States

MUMBAI Fri Nov 23, 2012 11:50pm IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) has recalled its generic version of Pfizer Inc's (PFE.N) cholesterol-lowering drug Lipitor in the United States after certain batches were found to contain glass particles.

Ranbaxy's U.S. subsidiary, Ranbaxy Pharmaceuticals Inc, said the recall affects certain lots of 10-, 20- and 40-milligram doses of the drug, known generically as atorvastatin calcium. The 80-milligram dosage is not affected.

The company is conducting an investigation which it expects will take two weeks. It did not report any injuries connected to the tainted pills and did not say how the problem was discovered.

The recall could cause shortages of the drug in the United States, analysts said. Ranbaxy, the first company to introduce generic Lipitor after Pfizer's patent expired in November 2011, controls about 60 percent of the market, according Ross Muken, an analyst at ISI Group LLC.

"Given its dominant share of this high-volume drug, we are certain to see supply shortages over the next two weeks," Muken said. The near-term impact is likely to be felt most by retail pharmacies and more modestly by wholesalers, he added.

The recall is the latest in a series of manufacturing problems at Ranbaxy, which is operating under heightened scrutiny following a long-running dispute with the U.S. Food and Drug Administration.

In 2008 the FDA banned the company from importing about 30 drugs after it found manufacturing deficiencies at two of the company's facilities in India. In 2009 the U.S. government accused Ranbaxy of falsifying data used in drug applications.

Last December, Ranbaxy agreed to make changes to its manufacturing plants in the United States and India. And it said it would set aside $500 million to resolve any potential civil or criminal charges stemming from an investigation by the U.S. Department of Justice.

Under a proposed settlement earlier this year, Ranbaxy agreed to engage a third party to conduct a review of its facilities, implement procedures to ensure data integrity in its marketing applications, and ensure it meets good manufacturing practices.

During its first six months on the market, when it enjoyed marketing exclusivity, atorvastatin generated sales of nearly $600 million for Ranbaxy, according to Bhagwan Singh Chaudhary, a research associate at the brokerage IndiaNivesh.

"The (recall) will impact the company's credibility," said Chaudhary. "A recall suggests corrective measures suggested by the U.S. FDA are not being implemented."

Other drugmakers, including Indian rival Dr. Reddy's Laboratories Ltd (REDY.NS), have launched their own versions of Lipitor, and the market has become more competitive.

In 2008, Japan's Daiichi Sankyo Co (4568.T) acquired a majority stake in Ranbaxy in a deal valued at $4.2 billion.

Shares of Ranbaxy, which is valued at $3.93 billion, fell 3.3 pct to 496 rupees in Mumbai .BSESN. (Additional reporting by Toni Clarke in Boston. Editing by Chris Gallagher, Matt Driskill and John Wallace)

FILED UNDER:

Surprise Rate Cut

Reuters Showcase

Eicher Share Sale

Eicher Share Sale

Truck maker Volvo sells shares in Eicher Motors  Full Article 

Beef Ban

Beef Ban

After beef ban, Hindu groups force abattoirs to close   Full Article 

Services Growth

Services Growth

Services growth at eight-month high in Feb - HSBC PMI  Full Article 

StanChart Results

StanChart Results

StanChart rules out share sale as profit plunges 25 pct  Full Article 

Jim O’Neill Interview

Jim O’Neill Interview

'India can become world’s fifth-largest economy by decade’s end'  Full Article 

Coal Imports

Coal Imports

India coal imports in Feb jump from year ago, but drop m/m  Full Article 

Next Superhero

Next Superhero

Franchise Man swoops in to save Bollywood  Full Article 

Budget 2015

Budget 2015

Budget announcements and reactions from the industry  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage